Genentech Inc. (DNA) is in the Pharma Industry

• Sort by
• View by Content Type
• View Related Content by Tag

• NICE Rejects Cancer Drug in Clash With Roche

  LONDON/ZURICH (Reuters UK) - Roche's ROG cancer drug Avastin will not be made available for use on Britain's state health service because the Swiss drugmaker has refused to provide enough information to assess its cost-effectiveness. The National Institute for Clinical Health and Excellence NICE said...

  News items 2008-06-26

  Tags: Roche Holding AG, Health Service, Breast Cancer, Lung, Health Care, Avastin, NICE, Genentech Inc., Rogers Corp.

• Genentech: Britain's National Health Won't Pay for Avastin

  Michael Steinberg submits: The Financial Times “A dose of reality” explores the controversy over the British National Health Service's NHS refusal to pay for medical services for patients who use certain high cost drugs. The National Institute for Clinical Excellence NICE advises the NHS on the cost-benefit of drugs. Genentech’s...

  External links 2008-06-25

  Tags: Genentech Inc., Healthcare, Biotech

• Generex Biotechnology and the USMCI: Armed with Antigens in the War Against Breast Cancer

  R.J Steffens submits: The United States Military Cancer Institute has been investigating peptide based vaccines for therapuetic value in the war against breast cancer. Previous attempts at developing peptide vaccines for breast cancer had been largely disappointing. However, those vaccines were designed to treat metastatic disease. In contrast, the...

  External links 2008-06-23

  Tags: Biotech, Genentech Inc., Generex Biotechnology Corp.

• Biogen Idec Wins Proxy Fight Against Icahn

  By Toni Clarke CAMBRIDGE, Massachusetts (Reuters) - Biogen Idec Inc BIIB said on Thursday it has won a proxy fight against billionaire investor Carl Icahn, placing the biotechnology company on course to continue as an independent entity. Alexander Denner, managing director of the...

  News items 2008-06-19

  Tags: Corporate governance, Biogen Idec Inc., Carl Icahn, biotechnology company, biotechnology, Cambridge, billionaire investor, Massachusetts, shareholder, board, DNA, Thomson Reuters Corp., R&D, stock

• FDA Slaps Down Genentech On Eye Drug

  The saga of Avastin and Lucentis -- two Genentech drugs used to treat a blinding condition called age-related macular degeneration, even though one is about 50 times cheaper than the other -- is one of those stories that just gets better the longer it goes on. A...

  Blog posts 2008-06-17

  Tags: FDA, Genentech Inc., Avastin, Federal Government, Government, David P. Hamilton

• Genentech and Symphogen in $330M Alliance

  Eben Tessari submits: I try not to be biased, but it’s not too often I discuss danish biotech companies on this blog.  Today is different. We are having a full international day here at Pharmababble.  First the Daiichi news and now this release of a collaboration from Symphogen and Genentech...

  External links 2008-06-11

  Tags: Genentech Inc., Healthcare

• Genentech Q1 2008 Earnings Call Transcript

  Genentech Q1 2008 Earnings Call Transcript

  Earnings calls 2008-04-10

  Tags: Genentech Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

• Genentech Q4 2007 Earnings Call Transcript

  Genentech Q4 2007 Earnings Call Transcript

  Earnings calls 2008-01-14

  Tags: Genentech Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

• Genentech Q3 2007 Earnings Call Transcript

  Genentech Q3 2007 Earnings Call Transcript

  Earnings calls 2007-10-15

  Tags: Genentech Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

• Genentech Q2 2007 Earnings Call Transcript

  Genentech Q2 2007 Earnings Call Transcript

  Earnings calls 2007-07-11

  Tags: Genentech Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

• Genentech Q1 2007 Earnings Call Transcript

  Genentech Q1 2007 Earnings Call Transcript

  Earnings calls 2007-04-11

  Tags: Genentech Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

• Top-Down Productivity

  Three senior managers use David Allen’s personal-productivity system to get the most out of their teams. Making GTD a Team Sport Who: Steve Kowalski, Director of Learning & Development Where: Genentech When: Started GTD in 2002...

  Articles 2007-02-08

  Tags: Team management, Microsoft Office, Robert Landon, Genentech Inc., biomedical, Palm Treo, training, Palm Inc., Microsoft Outlook, team, director, e-mail, smart phone, worker, mouse, Microsoft Corp., software, marketing, phone

• Genentech Q4 2006 Earnings Call Transcript

  Genentech Q4 2006 Earnings Call Transcript

  Earnings calls 2007-01-10

  Tags: Genentech Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

• Genentech Q3 2006 Earnings Call Transcript

  Genentech Q3 2006 Earnings Call Transcript

  Earnings calls 2006-10-10

  Tags: Genentech Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

• Genentech, Inc. Q2 2006 Earnings Conference Call Transcript (DNA)

  Genentech, Inc. Q2 2006 Earnings Conference Call Transcript DNA

  Earnings calls 2006-07-12

  Tags: Genentech Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

• Genentech Inc. Q4 2005 Earnings Conference Call Transcript (DNA)

  Genentech Inc. Q4 2005 Earnings Conference Call Transcript DNA

  Earnings calls 2006-01-11

  Tags: Genentech Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

Additional Resources

• Genentech Announces July 14 Webcast of Financial and Other Business Results

  SOUTH SAN FRANCISCO, Calif. -- Genentech, Inc. (NYSE:DNA) will announce its 2008 second quarter financial results on Monday, July 14, 2008, after the close of the financial markets. The announcement will be followed by a live webcast with Genentech management at 1:45 p.m. Pacific Time. The webcast can...

  Articles 2008-06-23

• Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing

  BOTHELL, Wash. -- Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has achieved a milestone under its antibody-drug conjugate ADC collaboration with Genentech, Inc. The milestone was triggered by Genentech's filing of an Investigational New Drug IND application with the U.S. Food and Drug Administration FDA for an ADC utilizing...

  Articles 2008-06-18

• New Analyst Reports for HUMANA INC, AETNA INC, GENENTECH INC, and ABBOTT LABORATORIES

  MaybachFinancial.com is one of the fastest growingindependent and unbiased research firms in the world. Through our numerouspartnerships with many of the top investment minds in the world, we provideresearch on companies making a move in the markets. Investors seekinggenuine analyst opinions on their investments for HUMANA INC (NYSE: HUM),AETNA INC...

  Articles 2008-06-17

• Danish biopharmaceutical company Symphogen A/S signs strategic collaboration agreement with Genentech Inc

  NORDIC BUSINESS REPORT-11 June 2008-Danish biopharmaceutical company Symphogen A/S signs strategic collaboration agreement with Genentech IncC1994-2008 M2 COMMUNICATIONS LTD http://www.m2.com Danish biopharmaceutical company Symphogen A/S said on Tuesday (10 June) that it has signed a strategic collaboration agreement with the US drug developer Genentech Inc (NYSE:DNA). ...

  Articles 2008-06-11